Related Experiment Video

Updated: May 5, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population

Jun Wang, Li Jun Wang, Yong Zhong

  • 1Departments of Cardiology, School of Medicine, Nanjing University, Jinling Hospital/Nanjing General Hospital of Nanjing Military Command, 305 Zhongshan East Road, Nanjing, Jiangsu Province 210002, China. zero991127@hotmail.com.

Lipids in Health and Disease
|November 29, 2013
PubMed

Insights

Genetic variations in the cholesteryl ester transfer protein (CETP) gene, specifically rs708272, were linked to a reduced risk of coronary atherosclerosis. Another variation, rs1800775, influenced high-density lipoprotein cholesterol (HDL-C) levels in healthy Chinese individuals.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Atherosclerosis Research

Background:

  • Coronary atherosclerosis involves lipid accumulation in coronary arteries, a key aspect of coronary artery disease (CAD).
  • High-density lipoprotein cholesterol (HDL-C) plays a causal role in the development of coronary atherosclerosis.
  • Cholesteryl ester transfer protein (CETP) regulates plasma HDL-C levels, and its gene mutations are linked to HDL-C variations.

Purpose of the Study:

  • To investigate the association between HDL-C-related CETP gene polymorphisms and the risk of coronary atherosclerosis.
  • To evaluate the impact of specific CETP single nucleotide polymorphisms (SNPs) on HDL-C levels.

Main Methods:

  • A case-control study was conducted in China involving 420 patients with coronary atherosclerosis and 424 healthy controls.
  • Seven single nucleotide polymorphisms (SNPs) in the CETP gene were genotyped using TaqMan allelic discrimination assay.
  • Serum lipid levels were measured using standard laboratory methods, and associations were analyzed.

Main Results:

  • Carriers of rs708272 genotypes AA and GA+AA showed significantly lower risks of coronary atherosclerosis compared to the GG genotype (OR=0.55, P=0.003; OR=0.67, P=0.007).
  • These associations remained significant after adjusting for confounding factors like age, smoking, diabetes, and hypertension.
  • The rs1800775 polymorphism was significantly associated with serum HDL-C levels in healthy controls (P=0.04), and rs708272 was in linkage disequilibrium with rs1800775.

Conclusions:

  • The CETP rs708272 polymorphism may be associated with altered risk of coronary atherosclerosis.
  • The CETP rs1800775 polymorphism may influence serum HDL-C levels in healthy Chinese individuals.
  • These findings highlight the role of CETP gene variations in cardiovascular health.
Abstract

More Related Videos

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
160
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
14.8K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
349